×
About 4,378 results

ALLMedicine™ Aspergillosis Center

Research & Reviews  1,513 results

Impact of treatment duration on recurrence of chronic pulmonary aspergillosis.
https://doi.org/10.1016/j.jinf.2021.07.030
The Journal of Infection; Im Y, Jhun BW et. al.

Aug 1st, 2021 - Limited data exist on the optimal treatment duration for chronic pulmonary aspergillosis (CPA). We investigated the treatment outcome and recurrence rate according to treatment duration in CPA patients. A total of 196 patients who completed at lea...

Pharmacological management of antifungal agents in pulmonary aspergillosis: an updated ...
https://doi.org/10.1080/14787210.2021.1962292
Expert Review of Anti-infective Therapy; Echeverria-Esnal D, Martín-Ontiyuelo C et. al.

Jul 31st, 2021 - Aspergillus may cause different types of lung infections: invasive, chronic pulmonary or allergic bronchopulmonary aspergillosis. Pharmacological management with antifungals poses as a challenge. Patients diagnosed with pulmonary aspergillosis are...

Azole-resistant Aspergillus fumigatus in the environment: Identifying key reservoirs an...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8321103
PLoS Pathogens; Burks C, Darby A et. al.

Jul 30th, 2021 - Aspergillus fumigatus is an opportunistic human pathogen that causes aspergillosis, a spectrum of environmentally acquired respiratory illnesses. It has a cosmopolitan distribution and exists in the environment as a saprotroph on decaying plant ma...

In vitro activity of APX2041, a new GWT1-inhibitor and in vivo efficacy of the prodrug ...
https://doi.org/10.1128/AAC.00682-21
Antimicrobial Agents and Chemotherapy; Shaheen SK, Juvvadi PR et. al.

Jul 27th, 2021 - Invasive aspergillosis (IA) due to Aspergillus fumigatus is a deadly infection for which new antifungal therapies are needed. Here we demonstrate the efficacy of a Gwt1 inhibitor, APX2041, and its prodrug, APX2104, against A. fumigatus. The wild-t...

Aiming for a bull's-eye: Targeting antifungals to fungi with dectin-decorated liposomes.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8297870
PLoS Pathogens; Meagher RB, Lewis ZA et. al.

Jul 23rd, 2021 - Globally, there are several million individuals with life-threatening invasive fungal diseases such as candidiasis, aspergillosis, cryptococcosis, Pneumocystis pneumonia (PCP), and mucormycosis. The mortality rate for these diseases generally exce...

see more →

Guidelines  8 results

Microbiological Laboratory Testing in the Diagnosis of Fungal Infections in Pulmonary a...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6727169
American Journal of Respiratory and Critical Care Medicine; Hage CA, Carmona EM et. al.

Aug 31st, 2019 - Background: Fungal infections are of increasing incidence and importance in immunocompromised and immunocompetent patients. Timely diagnosis relies on appropriate use of laboratory testing in susceptible patients.Methods: The relevant literature r...

ESCMID-ECMM guideline: diagnosis and management of invasive aspergillosis in neonates a...
https://doi.org/10.1016/j.cmi.2019.05.019
Clinical Microbiology and Infection : the Official Public... Warris A, Lehrnbecher T et. al.

Jun 4th, 2019 - Presenting symptoms, distributions and patterns of diseases and vulnerability to invasive aspergillosis (IA) are similar between children and adults. However, differences exist in the epidemiology and underlying conditions, the usefulness of newer...

Individualized Medication of Voriconazole: A Practice Guideline of the Division of Ther...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6250289
Therapeutic Drug Monitoring; Chen K, Zhang X et. al.

Sep 8th, 2018 - Voriconazole (VRZ) is a second-generation triazole antifungal agent with broad-spectrum activity. It is available in both intravenous and oral formulations, and is primarily indicated for treating invasive aspergillosis. The most commonly used dos...

Diagnosis and management of Aspergillus diseases: executive summary of the 2017 ESCMID-...
https://doi.org/10.1016/j.cmi.2018.01.002
Clinical Microbiology and Infection : the Official Public... Ullmann AJ, Aguado JM et. al.

Mar 17th, 2018 - The European Society for Clinical Microbiology and Infectious Diseases, the European Confederation of Medical Mycology and the European Respiratory Society Joint Clinical Guidelines focus on diagnosis and management of aspergillosis. Of the numero...

ECIL-6 guidelines for the treatment of invasive candidiasis, aspergillosis and mucormyc...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5394968
Haematologica Tissot F, Agrawal S et. al.

Dec 25th, 2016 - The European Conference on Infections in Leukemia (ECIL) provides recommendations for diagnostic strategies and prophylactic, pre-emptive or targeted therapy strategies for various types of infection in patients with hematologic malignancies or he...

see more →

Drugs  88 results see all →

Clinicaltrials.gov  69 results

Study to Evaluate the Safety and Efficacy of the Coadministration of Ibrexafungerp (SCY-078) With Voriconazole in Patients With Invasive Pulmonary Aspergillosis
https://clinicaltrials.gov/ct2/show/NCT03672292

Nov 18th, 2019 - This is a multicenter, randomized, double-blind, two-arm study to evaluate the safety, tolerability, efficacy and PK of the coadministration of SCY-078 plus voriconazole compared to those of voriconazole in male and female subjects 18 years of age...

Caspofungin Versus Fluconazole in Preventing Invasive Fungal Infections (IFI) in Patients Undergoing Chemotherapy for Acute Myeloid Leukemia
https://clinicaltrials.gov/ct2/show/NCT01307579

Sep 17th, 2019 - PRIMARY OBJECTIVES: I. To determine if prophylaxis with caspofungin administered during periods of neutropenia following chemotherapy for acute myeloid leukemia (AML) is associated with a lower incidence of proven or probable invasive fungal infec...

Chronic Pulmonary Aspergillosis and Ambisome Aerosol With Itraconazole
https://clinicaltrials.gov/ct2/show/NCT03656081

Jun 21st, 2019 - This study compares the therapeutic (clinical and radiological) efficacy of a six-month treatment by itraconazole and nebulised Ambisome® (liposomal amphotericin B = LAmB) versus treatment by itraconazole alone, in non - or mildly - immunocompromi...

Analysis T Cells Response for Identification of Aspergillus Bronchitis With Cystic Fibrosis Patients
https://clinicaltrials.gov/ct2/show/NCT02550041

May 9th, 2019 - The study aims to asses the ability of cell tests based on the analysis of the anti-Aspergillus cell responses and identify Aspergillus bronchitis with patients with cystic fibrosis. In addition, the study will evaluate the contribution of biologi...

Isavuconazole (BAL8557) for Primary Treatment of Invasive Aspergillosis
https://clinicaltrials.gov/ct2/show/NCT00412893

Apr 5th, 2019 - Acute invasive fungal infections caused by aspergillus, zygomycetes and other filamentous fungi remain life threatening diseases. Early treatment with highly effective anti-fungals reduces mortality. This study investigates the efficacy and safety...

see more →

News  67 results

Doctors Search for Missing Link Between COVID and ITP
https://www.medscape.com/viewarticle/944801

Jan 27th, 2021 - Editor's note: Find the latest COVID-19 news and guidance in Medscape's Coronavirus Resource Center. Hospitalist Sarah Stone, MD, arrived for her dayshift at Sharp Chula Vista in California one day in late December. The ICU and hospital wards were...

The COVID Complication You Might Miss
https://www.medscape.com/viewarticle/940740_2

Nov 19th, 2020 - COVID-Associated Pulmonary Aspergillosis (CAPA)   CAPA is a recently recognized complication of COVID-19. Although aspergillosis is classically associated with severely immunocompromised patients, it is increasingly detected in patients who receiv...

PJP prophylaxis may be unnecessary for CLL patients on BTK inhibitors
https://www.mdedge.com/chestphysician/article/210199/cll/pjp-prophylaxis-may-be-unnecessary-cll-patients-btk-inhibitors?channel=234
Sharon Worcester, MDedge News

Oct 16th, 2019 - EDINBURGH – Routine empiric prophylaxis against pneumocystis jiroveci pneumonia (PJP) may be unwarranted in chronic lymphocytic leukemia patients initiating Bruton tyrosine kinase (BTK) inhibitor therapy, a retrospective chart review suggests. Dr.

Myositis Patients at High Risk of Opportunistic Infections
https://www.medpagetoday.com/rheumatology/generalrheumatology/82747

Oct 15th, 2019 - Among patients with systemic rheumatic diseases, the highest incidence of opportunistic infections was seen in those with polymyositis/dermatomyositis (PM/DM), Taiwanese researchers found. In a nationally representative cohort study, the incidence...

Fatal Drug-Resistant Invasive Pulmonary Aspergillus fumigatus in a 56-Year-Old Immunosuppressed Man
https://www.mdedge.com/fedprac/article/171981/hematology/fatal-drug-resistant-invasive-pulmonary-aspergillus-fumigatus-56/page/0/2?channel=327

Aug 14th, 2019 - Conclusion This fatal case of invasive pulmonary aspergillosis illustrates the importance of considering the 4 main causes of treatment failure in an infection. Although the patient had a high burden of disease with a rare resistance pattern, he w.

see more →

Patient Education  6 results see all →